Expanding beyond its biosimilars business, Coherus Biosciences has agreed to acquire Surface Oncology, a clinical stage immuno-oncology company, in a transaction worth up to US$65 M. Through the deal, Coherus doubles the size of its immunotherapy franchise, gaining access to Surface’s clinical stage antibodies, SRF388 and SRF114, for the treatment of cancer. Despite specialising in biosimilar development, Coherus is already investigating two immuno-oncology assets licensed from Junshi Biosciences – one of which is currently under US FDA review.